Glimepiride Zydus (Glimepiride)

Glimepiride Zydus is indicated for the oral treatment of hyperglycemia in patients with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents are insufficient.

• Adjunct to lifestyle modification for adults with newly diagnosed type 2 diabetes.
• Combination therapy with metformin when monotherapy does not achieve target glycemic control.
• Use in patients whose pancreatic β‑cell function is preserved.
• Management of fasting and post‑prandial blood glucose levels.
• Part of a stepwise treatment algorithm as recommended by diabetes guidelines.

The safety profile of glimepiride includes a range of observed adverse effects, which are generally categorized by frequency and severity.

Common

• Mild hypoglycemia, especially when meals are missed or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic skin reactions such as rash, urticaria, or angio‑edema.
• Hematologic abnormalities like leukopenia or thrombocytopenia (rare).

When prescribing Glimepiride Zydus, clinicians should consider several precautionary measures to minimize risk and ensure appropriate use.

• Assess renal and hepatic function before initiating therapy and monitor periodically.
• Avoid use in patients with a history of severe hypoglycemia.
• Use cautiously in the elderly, who may be more sensitive to glucose‑lowering effects.
• Do not initiate during pregnancy or lactation unless the benefit outweighs potential risks.
• Educate patients on recognizing signs of hypoglycemia and proper carbohydrate intake.
• Adjust dose or discontinue if concomitant medications that potentiate hypoglycemia are added.

Glimepiride Zydus can interact with other drugs that affect blood glucose levels or alter its metabolism, requiring dose adjustments or avoidance.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemic effects.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can increase glimepiride plasma concentrations.
• Monoamine oxidase inhibitors (MAOIs) that may potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may reduce glucose tolerance.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal function and glucose control.